Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.

Oncotarget · 2016 · PMC5095077 · PMID 27119503

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

But since i) there is no direct demonstration of similar efficacy of potentiation by cisplatin or cetuximab, ii) the subgroup analysis of patients irradiated with cisplatin did not achieve significance, no definitive conclusion could be drawn.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.